Evidence map›Paper›PMID 41024847›Full record

ReviewWorld journal of clinical oncology2025

Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven.

Alberto D'Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi, Giandomenico Roviello

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alberto D'AngeloDepartment of Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S57A7, United Kingdom.
Martina CatalanoDepartment of Health Sciences, Section of Clinical Pharmacology Oncology, University of Florence, Florence 50134, Italy.
Irene De Gennaro AquinoSchool of Human Health Sciences, University of Florence, Florence 50134, Tuscany, Italy.
Valeria GangiSchool of Human Health Sciences, University of Florence, Florence 50134, Tuscany, Italy.
Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology Oncology, University of Florence, Florence 50134, Italy. giandomenico.roviello@unifi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic urothelial carcinoma (mUC) is a challenging malignancy with historically limited treatment options. Advances in understanding its biology have enabled the development of innovative therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs, such as enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan, represent transformative advancements, offering targeted delivery of cytotoxic agents. This review highlights the evolving role of ADCs in mUC, examining their mechanisms, clinical efficacy, patient selection criteria, genetic insights, and future directions in personalized treatment strategies.

Indexed as

Antibody-drug conjugatesClinical efficacyEnfortumab vedotinMetastatic urothelial carcinoma

Identifiers

PMID41024847
PMCPMC12476608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.